The volume of data is exploding, and that is challenging drug makers' ability to transform big data into additional revenue. But companies who can exploit big data and analytics will have the potential to improve their productivity and efficiency, especially in the discovery, research and development of new products, experts say.
McKinsey has predicted big data could reduce research and development costs for pharmaceutical makers by $40 billion to $70 billion. They anticipate that data will form the cornerstone of future value-based assessment and also be used for gaining market access, and enhance competitiveness.
Join us in London on 23rd September to understand how to capture the value of data to reduce costs in research and development.
8 reasons to attend:
1) Improve the speed of decision making for both clinical and commercial functions by capturing the value of big data
2) Assess how big data management can help identify safety and operation signals to avoid unnecessary delays in RandD
3) Adopt a data-driven approach in drug evaluation and gain insight into the entire consumer experience
4) Learn how you can avoid adverse events by driving the value of real-world evidence data
5) Enhance efficiency in developing new products with in-silico modelling and simulation
6) Ensure data quality and turn the "noise" into valuable insight
7) Extend your knowledge on how to use data collaboratively and network with stakeholders
8) Evaluate the rewards of data management and how to measure ROI for big data initiatives
Early Bird Offer - Book before September 5th: GBP760
Standard Ticket: GBP795
Speakers: Dr David Morley, François-Henri Boissel, Tim Miller, Erwan David, Mr Stephen Doogan
+44 207 608 7071